Antitumor properties of a vanadyl(iv) complex with the flavonoid chrysin [VO(chrysin)2EtOH]2 in a human osteosarcoma model: the role of oxidative stress and apoptosisElectronic supplementary information (ESI) available. See DOI: 10.1039/c3dt50524c
Flavonoids, a polyphenolic compound family, and the vanadium compounds have interesting biological, pharmacological, and medicinal properties. We report herein the antitumor actions of the complex [VO(chrysin) 2 EtOH] 2 (VOchrys) on the MG-63 human osteosarcoma cell line. Oxovanadium( iv ), chrysin...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
31.07.2013
|
Online Access | Get full text |
Cover
Loading…
Summary: | Flavonoids, a polyphenolic compound family, and the vanadium compounds have interesting biological, pharmacological, and medicinal properties. We report herein the antitumor actions of the complex [VO(chrysin)
2
EtOH]
2
(VOchrys) on the MG-63 human osteosarcoma cell line. Oxovanadium(
iv
), chrysin and VOchrys caused a concentration-dependent inhibition of cell viability. The complex was the strongest antiproliferative agent (
p
< 0.05). Cytotoxicity and genotoxicity studies also showed a concentration effect. Reactive oxygen species (ROS) and the alterations in the GSH/GSSG ratio underlie the main mechanisms of action of VOchrys. Additions of ROS scavengers (vitamin C plus vitamin E) or GSH to the viability experiments demonstrated beneficial effects (
p
< 0.01). Besides, the complex triggered apoptosis, disruption of the mitochondria membrane potential (MMP), increased levels of caspase 3 and DNA fragmentation measured by the sub-G1 peak in cell cycle arrest experiments (
p
< 0.01). Collectively, VOchrys is a cell death modulator and a promissory complex to be used in cancer treatments.
Antitumor properties of a vanadium(
iv
) complex with chrysin were evaluated in MG-63 osteosarcoma cells, studied by cyto-, genotoxicity and apoptosis. |
---|---|
Bibliography: | 10.1039/c3dt50524c Electronic supplementary information (ESI) available. See DOI |
ISSN: | 1477-9226 1477-9234 |
DOI: | 10.1039/c3dt50524c |